Norditropin®

DRUG5 trials

Conditions

Growth Hormone DeficiencyGrowth Hormone Deficiency in ChildrenSGA, Turner Syndrome, Noonan Syndrome, ISSShort Stature Children Born Small for Gestational Age (SGA)

Phase 2

A Research Study in Children Born Small and Who Stayed Small. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day

Active, not recruitingNCT03878446

Novo Nordisk A/SShort Stature Children Born Small for Gestational Age (SGA)

Start: 2019-07-04End: 2026-12-23Updated: 2026-08-13

Safety and Efficacy of Y-shape Pegylated Somatropin in Growth Hormone Deficiency Children

CompletedNCT04513171

Xiamen Amoytop Biotech Co., Ltd.Growth Hormone Deficiency

Start: 2018-12-26End: 2023-07-10Updated: 2024-01-24

Phase 3

A Research Study in Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day (REAL4)

CompletedNCT03811535

Novo Nordisk A/SGrowth Hormone Deficiency in Children

Start: 2019-05-20End: 2025-09-30Updated: 2026-05-22

A Research Study in Chinese Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day.

CompletedNCT04970654

Novo Nordisk A/SGrowth Hormone Deficiency in Children

Start: 2021-07-22End: 2023-12-18Updated: 2026-01-06

A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow

Active, not recruitingNCT05330325

Novo Nordisk A/SSGA, Turner Syndrome, Noonan Syndrome, ISS

Start: 2022-08-10End: 2027-10-29Updated: 2026-06-12

2026-08-01

Once-weekly Somapacitan in Children with Noonan Syndrome: Randomised Controlled Phase 3 Trial.

2026-03-03

Somapacitan in children with idiopathic short stature: a randomised controlled phase 3 study.

2026-02-19

Somapacitan in Children Born Small for Gestational Age: 4-year Results from Phase 2

European Journal of Endocrinology2026-01-27

SAT-212 Long-term Safety And Efficacy Of Somapacitan In Short Children Born Small For Gestational Age: 4-year Results From A Global Phase 2 Trial

Journal of the Endocrine Society2025-10-01

OR03-06 Acutely regulated genes in children born small for gestational age following daily and weekly growth hormone are predictive of first-year growth response

Journal of the Endocrine Society2025-10-01

SAT-187 Efficacy And Safety Of Somapacitan In Non-GHD Adolescents With Short Stature: 26-week Results From The REAL9 Phase 3 Study

Journal of the Endocrine Society2025-10-01

Somapacitan is Effective and Well Tolerated in Chinese Children with Growth Hormone Deficiency: a Randomised Controlled Phase 3 Study

Hormone Research in Paediatrics2025-05-052 citations

Efficacy, safety, and insulin-like growth factor I of weekly somapacitan in children with growth hormone deficiency: 3-year results from REAL4

European Journal of Endocrinology2025-04-303 citations

12423 Pre-treatment Blood Transcriptome Accurately Predicts Growth Response To Daily And Weekly GH Treatment In Children Born Small For Gestational Age

Journal of the Endocrine Society2024-10-011 citations

12256 Sustained Efficacy Of Weekly Somapacitan In Children With GHD: 3-year Results From Phase 3 REAL4 Study

Journal of the Endocrine Society2024-10-01

Somapacitan in Children Born SGA: 52-Week Efficacy, Safety, and IGF-I Response Results From the Phase 2 REAL5 Study

The Journal of Clinical Endocrinology & Metabolism2024-09-134 citations

Investigating the Bioavailability and Insulin-like Growth Factor-I Release of Two Different Strengths of Somapacitan: A Randomised, Double-Blind Crossover Trial

Clinical Pharmacokinetics2024-07-011 citations

Effective growth hormone replacement with once‐weekly somapacitan in Japanese children with growth hormone deficiency: Results from REAL4, a phase 3 clinical trial

Clinical Endocrinology2024-02-189 citations

Gene Expression Signatures Predict First-Year Response to Somapacitan Treatment in Children With Growth Hormone Deficiency

The Journal of Clinical Endocrinology & Metabolism2023-12-085 citations

SAT642 Effective Gh Replacement With Once-weekly Somapacitan In Children With Gh Deficiency: 2-year Results From Real4

Journal of the Endocrine Society2023-10-01

THU174 Model-Based Analysis Of IGF-I Response, Dosing, And Monitoring For Once-Weekly Somapacitan In Children With GH Deficiency

Journal of the Endocrine Society2023-10-01

SAT643 Patient Preference Questionnaire Response After Switching To Somapacitan After Taking Daily Gh: 2-year Results From REAL4

Journal of the Endocrine Society2023-10-01

Model-Based Analysis of IGF-I Response, Dosing, and Monitoring for Once-Weekly Somapacitan in Children With GH Deficiency

Journal of the Endocrine Society2023-09-0812 citations

Effective GH Replacement With Somapacitan in Children With GHD: REAL4 2-year Results and After Switch From Daily GH

The Journal of Clinical Endocrinology & Metabolism2023-07-0520 citations

7 more papers not shown

Norditropin®

Sponsors

Conditions

Phase 2

Phase 3

Related Papers